A method for detecting related substances in rifampicin and its application in MNP monitoring
A high-performance liquid chromatography method with a specific mobile phase and stationary phase, using quinone rifampicin as a pointer impurity, addresses the challenges of detecting rifampicin-related substances and MNP, enhancing detection efficiency and reducing safety risks.
Patent Information
- Application Number
- CN202211262270.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-10-14
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2042-10-14
AI Technical Summary
Current methods for detecting genotoxic impurities in rifampicin, such as MNP, are hindered by the high cost and scarcity of high-sensitivity mass spectrometers, and existing pharmacopoeia methods fail to effectively separate rifampicin-related substances, posing a risk of MNP exceeding safety standards.
A method using high-performance liquid chromatography with a specific mobile phase and stationary phase, employing quinone rifampicin as a pointer impurity, to accurately detect rifampicin-related substances and monitor MNP content, utilizing a C8 chromatographic column, mobile phases A and B, and gradient elution.
The method enhances detection efficiency and accuracy, allowing for effective monitoring of MNP content, reducing the risk of exceeding safety standards, and improving inspection efficiency.
Smart Images

Figure CN115656364B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of drug detection, and in particular to a method for detecting related substances in rifampicin and an application thereof in MNP monitoring. Background Art
[0002] Genototoxic impurities (GTI) refer to substances that can directly or indirectly damage cell DNA, cause DNA mutations and pose a carcinogenic threat to human health.
[0003] Nitrosamine genotoxic impurities are one of the more harmful impurities and are listed in the "special concern queue".
[0004] Genotoxic impurities can cause great harm to patients, and even trace levels can induce DNA mutations. Moreover, the harm of this impurity to the human body is not dose-related. Therefore, the evaluation and limit control of genotoxic impurities are crucial. From the source of impurities, it is not possible and unnecessary to completely remove impurities. However, appropriate analytical methods can be used to find out the indicator impurities related to the generation of genotoxic impurities, which can effectively grasp the generation of genotoxic impurities, thereby improving the production process in a targeted manner, avoiding the lack of a highly sensitive mass spectrometer and the inability to evaluate the generation of genotoxic impurities. At the same time, it also provides a basis for the control of indicator impurity standards.
[0005] Rifampicin is an important anti-tuberculosis drug and one of the most in-demand drugs for tuberculosis on the market. Once tuberculosis patients take the drug, they must take it for a long time and cannot stop taking it midway, so the detection and monitoring of the genotoxic impurity MNP are crucial. At present, LC-MS technology is generally used to detect trace amounts of genotoxic impurities MNP. However, high-sensitivity mass spectrometers are expensive and not common among manufacturers, making it impossible to detect MNPs in the rifampicin they produce in a timely manner. At the same time, the current methods for detecting rifampicin-related substances in the European Pharmacopoeia, Japanese Pharmacopoeia, and Chinese Pharmacopoeia cannot meet the detection requirements for the separation of rifampicin, quinone rifampicin, and surrounding impurities (such as Figure 2-4 as shown). Summary of the invention
[0006] In order to solve the above technical problems, the present invention provides a method for detecting related substances in rifampicin and its application in MNP monitoring.
[0007] In the first aspect, the present invention provides a method for detecting related substances in rifampicin, including the preparation of a test solution and a control solution, using high performance liquid chromatography to determine the content of rifampicin and related substances in rifampicin, using quinone rifampicin as a pointer impurity, and using high performance liquid chromatography to monitor the content of the genotoxic impurity MNP of rifampicin; a C8 chromatographic column is used as the stationary phase; mobile phase A is a solution containing potassium dihydrogen phosphate and citric acid, and mobile phase B contains methanol and acetonitrile.
[0008] The present invention adopts a specific mobile phase and a stationary phase to more accurately detect rifampicin-related substances. At the same time, the method for detecting rifampicin-related substances developed and established by the present invention - using a pointer impurity to monitor the MNP content can effectively monitor the MNP content, reduce the risk of MNP exceeding the standard, and improve the inspection efficiency.
[0009] According to the present invention, the causes of the generation of nitrosamine compounds are complex and diverse, and may come from the production process, mainly including side reactions occurring in drug synthesis, generating N-nitrosamine impurities with genetic toxicity, such as secondary amine compounds interacting with nitrosating agents such as nitrous acid. Nitroamine reduction reaction at high temperature, and hydrazine compounds undergoing redox reaction during drug production or storage. It may also come from catalysts, storage processes, packaging materials, and parallel production. The inventors verified the structures of rifampicin and MNP and experimentally confirmed that the formation of MNP in rifampicin is mainly related to oxidation reactions. By comparing the sources of the genetic toxic impurity MNP in rifampicin and the impurity spectra of rifampicin with different MNP contents, it was found that the content of quinone rifampicin in rifampicin capsules was correlated with MNP, so the present invention uses quinone rifampicin as a pointer-type impurity for monitoring the content of MNP in rifampicin.
[0010]
[0011] Preferably, the mobile phase A is 0.07-0.08 mol / L potassium dihydrogen phosphate solution and 0.9-1.1 mol / L citric acid solution in a volume ratio of 8-10:1 (0.07-0.08 mol / L potassium dihydrogen phosphate-0.9-1.1 mol / L citric acid solution (8-10:1)); preferably 0.075 mol / L potassium dihydrogen phosphate-1 mol / L citric acid solution (9:1).
[0012] Further preferably, the mobile phase B is methanol-acetonitrile, and the volume ratio of methanol to acetonitrile is 1-2:1-2, preferably 1: 1. Under this ratio, the separation effect of various impurities of rifampicin is good, and the separation degree meets the requirements.
[0013] Further preferably, the stationary phase is a Symmetry R C8 chromatographic column, 4.6×250 mm, 5 μm. This chromatographic column can shorten the elution time of each impurity in rifampicin, while ensuring a good separation effect and a more stable baseline.
[0014] Preferably, gradient elution is employed.
[0015] Further preferably, the elution procedure using gradient elution is:
[0016]
[0017] More preferably, the column temperature is in the range of 35±5°C, the injection volume is 10±2 μl, and the flow rate is 0.8-1.2 ml / min.
[0018] More preferably, the related substance is selected from one or more of quinone rifampicin, N-oxide rifampicin, rifamycin SV, and 3-formyl rifamycin SV.
[0019] Further preferably, the preparation of the test solution and the control solution includes: dissolving the capsules of the product with acetonitrile, adding 1 ml of acetonitrile for every 10 mg of the capsules of the product, and then quantitatively diluting with a solvent to prepare a solution containing 1 mg of rifampicin in 1 ml, filtering, and taking the filtrate as the test solution; diluting the test solution with a solvent to prepare a solution containing 10 μg of rifampicin in 1 ml as a control solution.
[0020] In the second aspect, the present invention also provides the application of the detection method of related substances in rifampicin in MNP monitoring, using quinone rifampicin as a pointer impurity of the genotoxic impurity MNP to monitor the genotoxic impurity MNP. Further preferably, when the quinone rifampicin content is 0.2%-0.7%, the MNP is 0.37-1.08 ppm, and when the quinone rifampicin content is 1.6%-1.9%, the MNP is 3.69-6.93 ppm. Preferably, the limit of quinone rifampicin in rifampicin capsules is set to 0.7%.
[0021] The beneficial effect of the present invention is at least that: the detection method of related substances in rifampicin provided by the present invention can effectively determine the impurities quinone rifampicin, N-rifampicin oxide, rifamycin SV and 3-formyl rifamycin SV in rifampicin. At the same time, the method of the present invention adopts quinone rifampicin as the indicator impurity of the genotoxic impurity MNP in rifampicin in HPLC technology. While better detecting the related substances of rifampicin, it can also monitor the content of MNP, reduce the risk of MNP exceeding the standard and improve the inspection efficiency. BRIEF DESCRIPTION OF THE DRAWINGS
[0022] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. It is obvious that the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.
[0023] Figure 1 Sample diagram provided for the present invention;
[0024] Figure 2 It is the European Pharmacopoeia (EP) system suitability diagram;
[0025] Figure 3 This is the sample diagram of the Japanese Pharmacopoeia (JP);
[0026] Figure 4 This is the sample picture of Chinese Pharmacopoeia (ChP);
[0027] Figure 5 A blank solvent diagram of rifampicin capsules provided by the present invention;
[0028] Figure 6 The linear relationship diagram of rifampicin provided by the present invention (0.5~1250 μg / ml);
[0029] Figure 7 The linear relationship diagram of quinone rifampicin provided by the present invention (0.5~100 μg / ml);
[0030] Figure 8 The linear relationship diagram of N-rifampicin oxide provided by the present invention (0.5~100 μg / ml);
[0031] Fig. 9 The linear relationship diagram of rifamycin SV provided by the present invention (0.5~100 μg / ml);
[0032] Fig.10 The linear relationship diagram of 3-formylrifamycin SV provided by the present invention (0.5~100 μg / ml);
[0033] Fig.11 The MNP content diagram provided by the present invention;
[0034] Fig.12 This is a graph showing the content of quinone rifampicin provided by the present invention. DETAILED DESCRIPTION
[0035] In order to make the purpose, technical solution and advantages of the present invention clearer, the technical solution of the present invention will be clearly and completely described below in conjunction with the drawings of the present invention. Obviously, the described embodiments are part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0036] If no specific techniques or conditions are specified in the examples, the techniques or conditions described in the literature in the field or the product instructions are used. If no manufacturer is specified for the reagents or instruments used, they are all conventional products that can be purchased through regular channels. Example
[0037] Determination method: Take 10 μl of the test solution and the control solution respectively and inject them into the liquid chromatograph, and record the chromatogram (see the typical chromatogram for details). Figure 1 ), measure the peak area, and calculate according to the correction factor principal component self-reference method.
[0038] Rifampicin reference substance: batch number 130496-200702, content is 98.0%, source is China Food and Drug Inspection Institute. Quinone rifampicin reference substance: batch number 130413-201605, content is 92.8%, source is China Food and Drug Inspection Institute. N-rifampicin oxide reference substance: batch number 130522-201102, content is 93.1%, source is China Food and Drug Inspection Institute. Rifamycin SV reference substance: batch number 130333-201508, content is equivalent to 847 units per mg, source is China Food and Drug Inspection Institute. 3-Formyl rifamycin SV reference substance: batch number 130414-201904, content is 92.3%, source is China Food and Drug Inspection Institute.
[0039] Experimental materials: Among the instruments and equipment, the liquid chromatography LC-20A (LAB SOLUTION) was used, the manufacturer was Shimadzu, the number was AAI443. The Symmetry R C8 chromatographic column was manufactured by Waters, the number was WAT054270. Among the other reagents and materials, methanol and acetonitrile were purchased from Fisher, and potassium dihydrogen phosphate and citric acid monohydrate were purchased from Sinopharm Chemical Reagent Co., Ltd.
[0040] Verification items and acceptable standards: Specificity: The blank solvent should have no interference at the peaks of quinone rifampicin, N-rifampicin oxide, rifamycin SV, and 3-formyl rifamycin SV. Sensitivity: 1. The signal-to-noise ratio of the quantitative limit solution S / N ≥ 10; 2. The signal-to-noise ratio of the detection limit solution S / N ≥ 3. Repeatability: The control solution with a concentration of 100 μg / ml was injected 6 times, and the relative standard deviation of the peak area obtained should not exceed 1.5%. Linearity and range: Calculate the linear regression equation, and the correlation coefficient (r) should not be less than 0.995. Accuracy: 1. The average recovery rate of quinone rifampicin solution should be between 92% and 105%; 2. The average recovery rate of N-rifampicin oxide solution should be between 90% and 108%; 3. The average recovery rate of rifamycin SV solution should be between 92% and 105%; 4. The average recovery rate of 3-formyl rifamycin SV solution should be between 90% and 108%; 5. The sample addition rate (%) of each concentration should not exceed 1.5%.
[0041] Solution preparation:
[0042] Solvent: acetonitrile-water (1:1).
[0043] Blank solution: Take the solvent as the blank solution.
[0044] System suitability solution: Weigh 4 mg of each of rifampicin reference substance, quinone rifampicin reference substance, N-oxide rifampicin reference substance, rifamycin SV reference substance, and 3-formyl rifamycin SV reference substance into a 10 ml volumetric flask, dissolve in 2 ml acetonitrile, and dilute to scale with acetonitrile-water (1:1). Measure 1 ml of the solution into a 10 ml volumetric flask, and dilute with acetonitrile-water (1:1) to make a mixed solution containing approximately 0.04 mg per 1 ml.
[0045] Sensitivity solution (detection limit solution): Accurately measure appropriate amounts of rifampicin reference substance and each impurity reference substance solution, and quantitatively dilute them with solvent to prepare solutions containing approximately 0.4 μg of rifampicin, 0.1 μg of quinone rifampicin, 32 ng of N-oxide rifampicin, 32 ng of rifamycin SV, and 32 ng of 3-formyl rifamycin SV per 1 ml.
[0046] Quantitation limit solution: Accurately measure appropriate amounts of rifampicin reference substance and each impurity reference substance solution, quantitatively dilute with solvent to make solutions containing approximately 0.5 μg per 1 ml.
[0047] Preparation of test solution: Take 1 capsule of this product, which is equivalent to about 150 mg of rifampicin, and place it in a 50 ml centrifuge tube. Accurately add 15 ml of acetonitrile, shake, and then accurately measure 1 ml and place it in a 10 ml volumetric flask. Dilute quantitatively with solvent to make a solution containing about 1 mg in 1 ml. Filter and take the filtrate.
[0048] Preparation of control solution: Accurately measure 0.1 ml of the above test sample filtrate and place it in a 10 ml volumetric flask, and quantitatively dilute it with solvent to make a solution containing about 10 μg in 1 ml.
[0049] Preparation of recovery solution: Accurately weigh appropriate amounts of quinone rifampicin, N-rifampicin oxide, rifamycin SV and 3-formyl rifamycin SV reference substances, dissolve them in appropriate amount of acetonitrile (about 10 mg in 1 ml acetonitrile), and then quantitatively dilute with solvent to prepare about 750 μg of quinone rifampicin solution, about 500 μg of N-rifampicin oxide solution, about 1000 μg of rifamycin SV solution, and about 500 μg of 3-formyl rifamycin SV solution in 1 ml respectively. In the rifampicin standard substance (10 mg was weighed and placed in a 10 ml volumetric flask, and dissolved in 1 ml of acetonitrile), the recovery test solution was accurately added to make the final concentration of quinone rifampicin in rifampicin low (12 μg / ml), medium (15 μg / ml), and high (18 μg / ml), the final concentration of N-oxide rifampicin was low (4 μg / ml), medium (5 μg / ml), and high (6 μg / ml), the final concentration of rifamycin SV was low (8 μg / ml), medium (10 μg / ml), and high (12 μg / ml), and the final concentration of 3-formyl rifamycin SV was low (4 μg / ml), medium (5 μg / ml), and high (6 μg / ml). Prepare three copies of each concentration in parallel as the recovery test solution.
[0050] Preparation of rifampicin standard curve solution: Accurately weigh an appropriate amount of rifampicin reference substance, dissolve it in an appropriate amount of acetonitrile (about 10 mg in 1 ml acetonitrile), and then quantitatively dilute it with solvent to make reference substance solutions of about 0.5 μg, 5 μg, 25 μg, 100 μg, 500 μg, 1000 μg, and 1250 μg in 1 ml.
[0051] Preparation of impurity standard curve solution: Accurately weigh appropriate amounts of quinone rifampicin reference substance, N-rifampicin oxide reference substance, rifamycin SV reference substance and 3-formylrifamycin SV reference substance, dissolve them in appropriate amount of acetonitrile (about 10 mg in 1 ml acetonitrile), and then quantitatively dilute with solvent to prepare reference substance solutions of about 0.5 μg, 5 μg, 10 μg, 25 μg, 50 μg, and 100 μg in 1 ml, respectively.
[0052] Chromatographic conditions: A Symmetry R C8 column (4.6×250mm, 5μm) was used; mobile phase A was 0.075 mol / L potassium dihydrogen phosphate-1 mol / L citric acid solution (9:1), and mobile phase B was methanol-acetonitrile (1:1), with gradient elution as shown in the table below; the column temperature was 35°C, and the injection volume was 10 μl.
[0053]
[0054] The retention time of the main component peak was about 31 minutes, and the order of peaks was quinone rifampicin peak, rifampicin peak, N-rifampicin oxide peak, rifamycin SV peak and 3-formyl rifamycin SV peak (relative retention times were approximately 0.5, 1.1, 1.2 and 1.6, respectively).
[0055] Method Validation:
[0056] 1) Specificity test
[0057] Accurately measure 10 μl of blank solution and capsule test solution and inject them into the liquid chromatograph to record the chromatogram. Results: The blank solvent has no interference at the peaks of quinone rifampicin, N-oxide rifampicin, rifamycin SV and 3-formyl rifamycin SV ( Figure 5 ).
[0058] 2) Limit of detection and limit of quantification
[0059] 10 μl of rifampicin, quinone rifampicin, N-oxide rifampicin, rifamycin SV and 3-formyl rifamycin SV limit of quantification solution and detection limit solution were accurately measured and injected into the liquid chromatograph, and the chromatograms were recorded. The results showed that the signal-to-noise ratio of the quinone rifampicin limit of quantification solution was S / N=10; the signal-to-noise ratio of the detection limit solution was S / N=3, and the signal-to-noise ratio of the N-oxide rifampicin limit of quantification solution was S / N=13; the signal-to-noise ratio of the detection limit solution was S / N=6, and the signal-to-noise ratio of the rifamycin SV limit of quantification solution was S / N=12; the signal-to-noise ratio of the detection limit was S / N=5, the signal-to-noise ratio of the 3-formyl rifamycin SV limit of quantification solution was S / N=21, the signal-to-noise ratio of the detection limit solution was S / N=15, the signal-to-noise ratio in the rifampicin limit of quantification solution was S / N=11, and the signal-to-noise ratio of the rifampicin solution in the detection limit solution was S / N=6; the detection sensitivity requirements were met.
[0060]
[0061] 3) Precision
[0062] Accurately measure the reference solution and inject it into the liquid chromatograph, record the chromatogram, repeat the injection 6 times, and the relative standard deviation of the peak area calculated is 0.6%, indicating good precision.
[0063] 4) Repeatability
[0064] Take rifampicin with batch number 130496-202204, prepare 5 portions according to the test sample preparation method, and prepare the control solution according to the principal component self-control method with correction factor, inject it into the liquid chromatograph, and record the chromatogram. The SD of the contents of quinone rifampicin, N-oxidized rifampicin, rifamycin SV and 3-formyl rifamycin SV are all less than 0.006%, indicating that the method of the present invention has good repeatability.
[0065] 5) Stability
[0066] Take 10 μl of the test solution (since the content of impurities rifamycin SV and 3-formyl rifamycin SV is too low, add appropriate amount of rifamycin SV and 3-formyl rifamycin SV impurity reference substances to the test solution to investigate stability) and inject it into the liquid chromatograph at 4°C within 0, 1.1, 2.2, 3.3, 4.4, and 5.5 hours. Calculate the RSD of the peak area of each impurity. The results are shown in Table 3, and the stability is good within 5.5 hours.
[0067]
[0068] 6) Durability
[0069] The system suitability solution was taken to investigate the separation of each impurity under different flow rates, different temperatures, different chromatographic columns, and different initial mobile phase ratios. The results are shown in Tables 4 and 5. The results show that the stability is good when the flow rate is in the range of 0.8-1.2 ml / min, the temperature is in the range of 30℃-40℃, different brands of chromatographic columns, and the initial mobile phase ratio is in the range of 48-52 to 52-48.
[0070]
[0071] Note: Impurity A is the product of quinone rifampicin and N-oxide rifampicin.
[0072]
[0073] Note: Impurity A is the product of quinone rifampicin and N-oxide rifampicin.
[0074] 7) Inter-day precision
[0075] Under the same experimental conditions, 10 μl of the newly prepared test solution was taken at the same time for three consecutive days and injected into the liquid chromatograph. The RSD of each impurity content was calculated by the area normalization method. The results are shown in Table 6. The method of the present invention has good precision.
[0076]
[0077] 8) Linearity and range
[0078] Accurately measure the reference solution of rifampicin with a concentration range of 0.5-1250 μg / ml, the reference solution of quinone rifampicin, N-rifampicin oxide, rifamycin SV and 3-formyl rifamycin SV with a concentration range of 0.5-100 μg / ml, inject each into the liquid chromatograph, record the chromatogram, and make a linear regression of the solution concentration (X) against the peak area (Y). Draw a standard curve with concentration versus peak area, and the results are as follows: Figure 6-10 The results showed that the linear relationship was good in the concentration range of 0.5~1250 μg / ml for rifampicin, 0.5~100 μg / ml for quinone rifampicin, N-oxide rifampicin, rifamycin SV and 3-formyl rifamycin SV.
[0079] 9) Accuracy
[0080] Accurately add the recovery test solution to make the final concentration of the spike as shown in Table 7:
[0081]
[0082]
[0083] The above verification shows that the method of the present invention has good specificity, linearity, precision, stability, durability, accuracy, quantitative limit and detection limit. The method of the present invention can effectively detect MNP pointer impurities in rifampicin-quinone rifampicin and other related substances, such as Figure 1 .
[0084] The method of the present invention was used to detect rifampicin capsules with different MNP contents. The results showed that in rifampicin capsules, the quinone rifampicin content was correlated with the MNP content. Fig.12 When the quinone rifampicin content is 0.2%-0.7%, the MNP is 0.37-1.08 ppm, and when the quinone rifampicin content is 1.6%-1.9%, the MNP is 3.69-6.93 ppm, as shown in Table 12:
[0085]
[0086] The method of the present invention can be used as a method for detecting rifampicin related substances, and the impurity quinone rifampicin in rifampicin can be used as a pointer impurity of MNP in rifampicin in HPLC technology. While effectively detecting rifampicin related substances, the method of the present invention can also monitor the content of MNP. The limit of quinone rifampicin in rifampicin capsules should be set to 0.7%, which can ensure that the content of MNP is lower than the provisional limit of FDA. If the limit is exceeded, there is a risk of MNP exceeding the standard, and it needs to be detected and controlled.
[0087] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or make equivalent replacements for some of the technical features therein. However, these modifications or replacements do not deviate the essence of the corresponding technical solutions from the spirit and scope of the technical solutions of the embodiments of the present invention.
Claims
1. A method for detecting related substances in rifampicin, characterized in that: The method includes the preparation of the test solution and the control solution, the determination of the content of rifampicin and related substances in rifampicin by high performance liquid chromatography, the monitoring of the content of the genotoxic impurity MNP of rifampicin by high performance liquid chromatography, the stationary phase using C8 chromatographic column, the mobile phase A is 0.075 mol / L potassium dihydrogen phosphate-1 mol / L citric acid solution 9:1, the mobile phase B is methanol-acetonitrile 1:1, the gradient elution program is:
2. The method for detecting related substances in rifampicin according to claim 1, characterized in that: The stationary phase is a Symmetry R C8 chromatographic column, 4.6×250 mm, 5 μm.
3. The method for detecting related substances in rifampicin according to claim 1, characterized in that: The column temperature was in the range of 35±5°C and the injection volume was 10±2 μl.
4. The method for detecting related substances in rifampicin according to any one of claims 1 to 3, characterized in that: The preparation of the test solution and the control solution includes: dissolving rifampicin capsules with acetonitrile, then quantitatively diluting with a solvent to prepare a solution containing 1 mg of rifampicin in 1 ml, filtering, and taking the filtrate as the test solution; diluting the test solution with a solvent to prepare a solution containing 10 μg of rifampicin in 1 ml as a control solution.
5. Application of the method for detecting related substances in rifampicin according to any one of claims 1 to 4 in MNP monitoring, characterized in that: Quinone rifampicin was used as an indicator impurity of the genotoxic impurity MNP to monitor the genotoxic impurity MNP.
6. The use according to claim 5, characterized in that: When the quinone rifampicin content was between 0.2% and 0.7%, the MNP was between 0.37 and 1.08 ppm, and when the quinone rifampicin content was between 1.6% and 1.9%, the MNP was between 3.69 and 6.93 ppm.
7. The use according to claim 6, characterized in that: The limit for quinone rifampicin in rifampicin capsules is set at 0.7%.
Citation Information
Patent Citations
Method for determining contents of rifampicin and impurities thereof in rifampicin capsule
CN107315059A
Method for separating and detecting rifampicin and related impurities in rifampicin for injection
CN113933399A
Preparation of rifamycin derivative
JP1980133384A
